These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26474202)

  • 21. Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease.
    Zhou R; Gu Y; Zhang B; Kong T; Zhang W; Li J; Shi J
    Clin Transl Gastroenterol; 2023 Apr; 14(4):e00575. PubMed ID: 36854062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Liver diseases. Non-alcoholic fatty liver disease].
    Bernal Reyes R
    Rev Gastroenterol Mex; 2010 Aug; 75 Suppl 1():181-3. PubMed ID: 20959244
    [No Abstract]   [Full Text] [Related]  

  • 23. [[Current approaches to diagnosing and treating nonalcoholic fatty liver disease].
    Drapkina OM; Deeva TA; Volkova NP; Ivashkin VT
    Ter Arkh; 2014; 86(10):116-23. PubMed ID: 25509904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current epidemiology and pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
    Chen DF; Sun WJ; Liu KJ; Wen LZ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):111-114. PubMed ID: 28297796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
    Başaranoğlu M; Örmeci N
    Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk.
    Oni ET; Kalathiya R; Aneni EC; Martin SS; Blaha MJ; Feldman T; Agatston AS; Blumenthal RS; Conceiçao RD; Carvalho JA; Santos RD; Nasir K
    Am J Cardiol; 2015 Jan; 115(1):34-9. PubMed ID: 25456868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
    Liu J; Wang G; Jia Y; Xu Y
    Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.
    Lonardo A; Ballestri S; Marchesini G; Angulo P; Loria P
    Dig Liver Dis; 2015 Mar; 47(3):181-90. PubMed ID: 25739820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of non-alcoholic fatty liver disease.
    Dyson J; Day C
    Dig Dis; 2014; 32(5):597-604. PubMed ID: 25034293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Chan HL; de Silva HJ; Leung NW; Lim SG; Farrell GC;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):801-8. PubMed ID: 17565632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RBBB is associated with an increased risk of NAFLD in young healthy individuals.
    İşcen S
    Int J Cardiol; 2013 Oct; 168(4):4056-7. PubMed ID: 23907039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The assessment of cardiovascular risk factors in patients with nonalcoholic fatty liver disease].
    Chubirko KI; Ivachevs'ka VV; Hechko MM; Chopeĭ IV; Stan MP; Koshelia II
    Wiad Lek; 2014; 67(2 Pt 2):332-4. PubMed ID: 25796862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Determinants of nonalcoholic fatty liver disease in men and women with type 2 diabetes].
    Trojak A; Idzior-Waluś B; Waluś-Miarka M; Małecki M
    Przegl Lek; 2014; 71(12):677-80. PubMed ID: 25951695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Tiopronin in treatment of severe non-alcoholic fatty liver disease.
    Tang MC; Cheng L; Qiu L; Jia RG; Sun RQ; Wang XP; Hu GY; Zhao Y
    Eur Rev Med Pharmacol Sci; 2014; 18(2):160-4. PubMed ID: 24488902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.
    Lonardo A; Ballestri S; Targher G; Loria P
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):629-50. PubMed ID: 25327387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners.
    Casler K; Trees K; Bosak K
    J Am Assoc Nurse Pract; 2020 Apr; 32(4):323-331. PubMed ID: 31274677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved.
    Song M; Xia L; Liu Q; Sun M; Wang F; Yang C
    Adv Exp Med Biol; 2018; 1088():413-433. PubMed ID: 30390263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.